Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer : FDA Approves Humira Biosimilar Abrilada for Multiple Conditions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/18/2019 | 07:15am EST

By Colin Kellaher

Pfizer on Monday said the U.S. Food and Drug Administration approved Abrilada, its biosimilar to AbbVie blockbuster Humira, for multiple inflammatory conditions.

The New York drug maker said the approval covers the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.

Pfizer said it currently plans to launch Abrilada in the U.S. in 2023 based on the terms of its 2018 licensing agreement with AbbVie.

Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells and are analogous to generic copies of traditional pill-form medicines.

Humira, used to treat diseases from rheumatoid arthritis to gut disorders, is the world's biggest-selling drug.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE -0.62% 86.44 Delayed Quote.-5.65%
PFIZER 0.08% 38.32 Delayed Quote.-12.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
07:02pBig Drugmakers Push Deeper Into Cancer Treatment -- 4th Update
DJ
04:23pBig Drugmakers Push Deeper Into Cancer Treatment -- 3rd Update
DJ
02:19pBig Drugmakers Push Deeper Into Cancer Treatment -- 2nd Update
DJ
08:18aBRISTOL MYERS SQUIBB : Pfizer - Findings Released from Real-World Data Analysis ..
AQ
08:18aSANGAMO THERAPEUTICS : and Pfizer Announce Updated Phase 1/2 Results Showing Sus..
AQ
08:17aPFIZER : Continued strong Cresemba sales trigger second sales milestone this yea..
AQ
08:17aAntares Pharma Social Media Campaign for XYOSTED Wins Marcom Platinum Award
AQ
12/07PFIZER : Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained..
BU
12/06PFIZER : ViiV Healthcare submits New Drug Application to the FDA for fostemsavir..
AQ
12/06GLAXOSMITHKLINE : ViiV Healthcare reaffirms future commitment to industry leadin..
AQ
More news
Financials (USD)
Sales 2019 51 867 M
EBIT 2019 19 843 M
Net income 2019 18 469 M
Debt 2019 29 928 M
Yield 2019 3,74%
P/E ratio 2019 11,3x
P/E ratio 2020 18,6x
EV / Sales2019 4,67x
EV / Sales2020 5,08x
Capitalization 212 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 43,15  $
Last Close Price 38,32  $
Spread / Highest target 43,5%
Spread / Average Target 12,6%
Spread / Lowest Target -3,44%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Mikael Dolsten Chief Scientific Officer
Lidia L. Fonseca Chief Technology Officer & EVP
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-12.28%211 902
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.45%263 079
MERCK AND COMPANY16.28%226 211
NOVARTIS22.87%208 547
BRISTOL-MYERS SQUIBB COMPANY15.33%140 534